Literature DB >> 17646931

Regulation of intracellular calcium release and PP1alpha in a mechanism for 4-hydroxytamoxifen-induced cytotoxicity.

Aliccia Bollig1, Liping Xu, Archana Thakur, Jiusheng Wu, Tuan H Kuo, Joshua D Liao.   

Abstract

Treatment with tamoxifen, or its metabolite 4-hydroxytamoxifen (4OHT), has cytostatic and cytotoxic effects on breast cancer cells in vivo and in culture. Although the effectiveness of 4OHT as an anti-breast cancer agent is due to its action as an estrogen receptor-alpha (ERalpha) antagonist, evidences show that 4OHT is also cytotoxic for ERalpha-negative breast cancer cells and can be effective therapy against tumors that lack estrogen receptors. These findings underscore 4OHT signaling complexities and belie the most basic understandings of 4OHT action and resistance. Here, we have investigated the effects of 4OHT on Ca2+ homeostasis and cell death in breast cancer cells in culture. Measurement of Ca2+ signaling in breast cancer cells showed that 4OHT treatment altered Ca2+ homeostasis and was cytotoxic for both an ERalpha+ and an ERalpha- cell line, MCF-7 and MDA-MB-231, respectively. Further investigation lead us to the novel discovery that 4OHT-induced increase of ATP-dependent Ca2+ release from the endoplasmic reticulum correlated with 4OHT-induced upregulation of protein phosphatase 1alpha (PP1alpha) and the inositol 1,4,5-trisphosphate receptor (IP3R). Blocking 4OHT-induced PP1alpha upregulation by siRNA strategy reduced the effects of 4OHT on both Ca2+ signaling and cytotoxicity. Results from these investigations strongly suggest a role for PP1alpha upregulation in a mechanism for 4OHT-induced changes to Ca2+ signaling that ultimately contribute to the cytotoxic effects of 4OHT.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17646931     DOI: 10.1007/s11010-007-9526-2

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  49 in total

1.  Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial.

Authors:  Victor G Vogel; Joseph P Costantino; D Lawrence Wickerham; Walter M Cronin; Reena S Cecchini; James N Atkins; Therese B Bevers; Louis Fehrenbacher; Eduardo R Pajon; James L Wade; André Robidoux; Richard G Margolese; Joan James; Scott M Lippman; Carolyn D Runowicz; Patricia A Ganz; Steven E Reis; Worta McCaskill-Stevens; Leslie G Ford; V Craig Jordan; Norman Wolmark
Journal:  JAMA       Date:  2006-06-05       Impact factor: 56.272

Review 2.  Mitochondria: a target for cancer therapy.

Authors:  Jeffrey S Armstrong
Journal:  Br J Pharmacol       Date:  2006-02       Impact factor: 8.739

3.  Role of mitochondria in tamoxifen-induced rapid death of MCF-7 breast cancer cells.

Authors:  A Kallio; A Zheng; J Dahllund; K M Heiskanen; P Härkönen
Journal:  Apoptosis       Date:  2005-12       Impact factor: 4.677

Review 4.  The pharmacology and clinical uses of tamoxifen.

Authors:  B J Furr; V C Jordan
Journal:  Pharmacol Ther       Date:  1984       Impact factor: 12.310

5.  A phase II study of carboplatin and chronic high-dose tamoxifen in patients with recurrent malignant glioma.

Authors:  P Tang; G Roldan; P M A Brasher; D Fulton; W Roa; A Murtha; J G Cairncross; P A Forsyth
Journal:  J Neurooncol       Date:  2006-05-19       Impact factor: 4.130

6.  Tamoxifen-induced enhancement of calcium signaling in glioma and MCF-7 breast cancer cells.

Authors:  W Zhang; W T Couldwell; H Song; T Takano; J H Lin; M Nedergaard
Journal:  Cancer Res       Date:  2000-10-01       Impact factor: 12.701

7.  Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial.

Authors:  C K Osborne; J Pippen; S E Jones; L M Parker; M Ellis; S Come; S Z Gertler; J T May; G Burton; I Dimery; A Webster; C Morris; R Elledge; A Buzdar
Journal:  J Clin Oncol       Date:  2002-08-15       Impact factor: 44.544

8.  Acceptance of tamoxifen chemoprevention by physicians and women at risk.

Authors:  Julia Tchou; Nanjiang Hou; Alfred Rademaker; V Craig Jordan; Monica Morrow
Journal:  Cancer       Date:  2004-05-01       Impact factor: 6.860

9.  Protein phosphatase 1alpha activity prevents oncogenic transformation.

Authors:  Cathy W Y Liu; Rui-Hong Wang; Norbert Berndt
Journal:  Mol Carcinog       Date:  2006-09       Impact factor: 4.784

10.  Age-related difference in tamoxifen disposition.

Authors:  F Peyrade; M Frenay; M C Etienne; F Ruch; C Guillemare; E François; M Namer; J M Ferrero; G Milano
Journal:  Clin Pharmacol Ther       Date:  1996-04       Impact factor: 6.875

View more
  8 in total

1.  Dual mechanisms of sHA 14-1 in inducing cell death through endoplasmic reticulum and mitochondria.

Authors:  David Hermanson; Sadiya N Addo; Anna A Bajer; Jonathan S Marchant; Sonia Goutam Kumar Das; Balasubramanian Srinivasan; Fawaz Al-Mousa; Francesco Michelangeli; David D Thomas; Tucker W Lebien; Chengguo Xing
Journal:  Mol Pharmacol       Date:  2009-06-26       Impact factor: 4.436

2.  Protein phosphatase 1 alpha enhances glucocorticoid receptor activity by a mechanism involving phosphorylation of serine-211.

Authors:  Melanie Patt; Joël Gysi; Nourdine Faresse; John A Cidlowski; Alex Odermatt
Journal:  Mol Cell Endocrinol       Date:  2020-06-22       Impact factor: 4.102

3.  MCF-7 breast carcinoma cells express ryanodine receptor type 1: functional characterization and subcellular localization.

Authors:  Carlos Saldaña; Mauricio Díaz-Muñoz; Anaid Antaramián; Adriana González-Gallardo; Pablo García-Solís; Verónica Morales-Tlalpan
Journal:  Mol Cell Biochem       Date:  2008-12-04       Impact factor: 3.396

4.  Evaluation of estrogenic, antiestrogenic and genotoxic activity of nemorosone, the major compound found in brown Cuban propolis.

Authors:  Mariana S Camargo; Aline M Prieto; Flavia A Resende; Paula K Boldrin; Cassia R P Cardoso; Mariana F Fernández; José Manuel Molina-Molina; Nicolás Olea; Wagner Vilegas; Osmany Cuesta-Rubio; Eliana A Varanda
Journal:  BMC Complement Altern Med       Date:  2013-07-31       Impact factor: 3.659

5.  Inositol 1,4,5-trisphosphate-induced Ca2+ signalling is involved in estradiol-induced breast cancer epithelial cell growth.

Authors:  Cécilia Szatkowski; Jan B Parys; Halima Ouadid-Ahidouch; Fabrice Matifat
Journal:  Mol Cancer       Date:  2010-06-21       Impact factor: 27.401

6.  Tamoxifen-elicited uterotrophy: cross-species and cross-ligand analysis of the gene expression program.

Authors:  Joshua C Kwekel; Agnes L Forgacs; Lyle D Burgoon; Kurt J Williams; Timothy R Zacharewski
Journal:  BMC Med Genomics       Date:  2009-04-28       Impact factor: 3.063

7.  Comparison of cytotoxicity and genotoxicity of 4-hydroxytamoxifen in combination with Tualang honey in MCF-7 and MCF-10A cells.

Authors:  Nik Soriani Yaacob; Nur Faezah Ismail
Journal:  BMC Complement Altern Med       Date:  2014-03-19       Impact factor: 3.659

8.  Dynamic Changes in the Global Transcriptome and MicroRNAome Reveal Complex miRNA-mRNA Regulation in Early Stages of the Bi-Directional Development of Echinococcus granulosus Protoscoleces.

Authors:  Yun Bai; Zhuangzhi Zhang; Lei Jin; Yongqiang Zhu; Li Zhao; Baoxin Shi; Jun Li; Gang Guo; Baoping Guo; Donald P McManus; Shengyue Wang; Wenbao Zhang
Journal:  Front Microbiol       Date:  2020-04-09       Impact factor: 5.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.